TAT-cyclo-CLLFVY

Cat. No. 5582

TAT-cyclo-CLLFVY cyclo(Cys-Leu-Leu-Phe-Val-Tyr)  Cys-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Pro-Pro-Gln

Price and Availability

For TAT-cyclo-CLLFVY pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Biological Activity

Selective HIF-1 dimerization inhibitor. Blocks protein-protein interaction of recombinant HIF-1α, but not HIF-2α, with HIF-1β (IC50 = 1.3 μM) . Inhibits hypoxia-induced HIF-1 activity, and decreases VEGF and CAIX expression in osteosarcoma and breast cancer cells in vitro. Also reduces tubularization of hypoxic HUVECs.

Technical Data

M.Wt:
2559.1
Formula:
C111H188N42O24S2
Sequence:
CLLFVY CGRKKRRQRRRPPQ*

(Modifications: Lactam bridge: Cys-1 to Tyr-6), Disulfide bridge: 1-1*)

Solubility:
Soluble to 1 mg/ml in water
Storage:
Store at -20°C
CAS No:
1446322-66-2

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.

Certificate of Analysis / Product Datasheet / Safety Data Sheet

Miranda et al (2013) A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. J.Am.Chem.Soc. 135 10418. PMID: 23796364.

If you know of a relevant reference for this product please let us know.

Citations are publications that use Tocris products.

Do you know of a great paper that uses TAT-cyclo-CLLFVY from Tocris? If so please let us know.

View Related Products by Product Action

Keywords: TAT-cyclo-CLLFVY, supplier, HIF-1a, 1b, 1beta, 1alpha, α, β, hypoxia, inducible, factor, cancer, angiogenesis, antiangiogenic, dimerization, inhibitors, inhibits, Tocris Bioscience, Hypoxia Inducible Factor Inhibitor products

Quick Order

Find multiple products by catalog number

divider line

Cancer Research Product Guide

Cancer Research Product Guide

Our Cancer Research Guide highlights over 750 products for cancer research. Request copy or view PDF today.

divider line

VEGF Pathway & Anti-Angiogenic Therapy

Written by N. Ferrara & Y. Crawford

Angiogenesis Life Science Poster

A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance. Request copy today.

divider line

New Products in this Area

RG 102240

Gene switch ligand for use in induceable gene expression systems

ML 334

Inhibitor of Keap1- Nrf2 interaction

RA 839

Nrf2 activator; inhibits Nrf2/Keap1 interaction

Sign-up for new product e-alerts
divider line

Bio-Techne Events

Pharmacology 2016

Pharmacology 2016

December 13 - 15, 2016

London, UK

Booth: 7